Articles Vol. 67 No. 1 15/01/2026

INVESTIGATION OF AN ORAL GLUCOCORTICOID-INDUCED OSTEOPOROSIS MOUSE MODEL

Chuong Thi Ngoc Hieu1,2, Ha Quang Thanh1,2, Mai Thanh Chung3,4, Bui Thanh Phong3,4, Chung Thi My Duyen5,6
1 Ho Chi Minh City Biotechnology Center
2 Trung Tâm Công Nghệ Sinh Học
3 Hong Bang International University
4 Trường Đại Học Quốc Tế Hồng Bàng
5 Faculty of Traditional Medicine - University of Medicine and Pharmacy at Ho Chi Minh City
6 Khoa YHCT - ĐH Y Dược TP Hồ Chí Minh
DOI: 10.52163/yhc.v67i1.4158
16 Views
12 Downloads
Keywords
Glucocorticoid-induced osteoporosis, alendronate, prednisone, phosphorus content in bone, calcium content in bone, …..
Abstract

Objective: This study investigated biochemical parameters in osteoporosis mouse model induced by prolonged glucocorticoid administration.

Materials  and  methods: Mice were orally administered prednisone at doses of 5, 10, and 20 mg/kg/day continuously for 6 and 8 weeks. Biochemical parameters, including bone weight, ash weight, bone phosphorus and calcium content were evaluated. The model’s responsiveness (optimal dose/duration) to the anti-osteoporosis drug alendronate (5 mg/kg) was also assessed at 4 weeks post-prednisone treatment.

Results: Prednisone administration significantly reduced bone weight, ash weight, bone phosphorus and calcium content, with the most pronounced effects observed at the 20 mg/kg dose over 8 weeks. Alendronate treatment at dose 5mg/kg effectively increased these parameters, restoring bone health indicators.

Conclusion: The mouse model of prednisone-induced osteoporosis (20 mg/kg/day for 8 weeks) is suitable for evaluating the anti-osteoporosis efficacy of drugs and formulations in preclinical research.

References
[1]
Nguyễn Thị Thanh Hải. Thực trạng sử dụng corticoid trong điều trị bệnh khớp tại Việt Nam. Tạp chí Y học Thực hành. 2020; 12(3): 45–50. Google Scholar
[2]
Jee W, Yao W. Overview: Animal models of osteopenia and osteoporosis. The Journal of Musculoskeletal and Neuronal Interactions. 2001;1(3):193-207. Google Scholar
[3]
Hà Quang Thanh. Mô phỏng mô hình gây loãng xương trên chuột nhắt trắng bằng glucocorticoid. [Luận văn Thạc sĩ ĐH KHTN TPHCM]. 2017: 26-27. Google Scholar
[4]
NAFIQAD. Quyết định ban hành qui trình phân tích chuẩn xác định hàm lượng phốt pho bằng phương pháp quang phổ. Hà Nội. 2011. Google Scholar
[5]
Bộ Khoa học và Công nghệ. Hướng dẫn quản lý hoạt động sử dụng động vật thí nghiệm. Thông tư số 04/2010/TT-BKHCN. 2010. Google Scholar
[6]
Komori T. Animal models for osteoporosis. European Journal of Pharmacology. 2015; (759): 287-294. doi.org/10.1016/j.ejphar.2015.03.028. Google Scholar
[7]
Canalis E. Glucocorticoid-induced osteoporosis: Google Scholar
[8]
Pathophysiology and therapy. Osteoporosis International. 2007; 8(10): 1319-1328. doi: 10.1007/s00198-007-0394-0. Google Scholar
[9]
Malik K., Khaldoyanidi S, Frincke J. 5-Androstene 3beta,7beta,17beta-triol (beta-AET) slows thermal injury induced osteopenia in mice: relation to aging and osteoporosis. PLoS One. 2010; 5(10) e13566. doi: 10.1371/journal.pone.0013566.C.T.M. Duyen et al. / Vietnam Journal of Community Medicine, Vol. 67, No. 1, 132-137137 Google Scholar
[10]
Hara K., Akiyama Y, Ohkawa I., Tajima T. Effects of menatetrenone on prednisolone-induced bone loss in rats. Bone. 1993; 14 (6): 813-818. doi:10.1016/87563282(93)90309-x. Google Scholar
[11]
Boskey L, Coleman R. Aging and bone. Journal of Dental Research. 2010; 89(12): 1333-1348. doi:10.1177/0022034510377791. Google Scholar
[12]
Weinstein R. Inhibition of osteoblastogenesis and Google Scholar
[13]
promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Journal of Clinical Investigation. 1998; 102(2): 274-282. doi: 10.1172/JCI2799. Google Scholar
[14]
Russell S. Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporosis International. 2008: 19(6): 733-759. doi: 10.1007/s00198-007-0540-8. Google Scholar